{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T19:25:57Z","timestamp":1787772357362,"version":"build-2784847793"},"reference-count":19,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,11]]},"abstract":"<jats:sec>\n                    <jats:title>OBJECTIVE:<\/jats:title>\n                    <jats:p>\n                      Although migraine is common, there are very few treatment options. Recently, lasmiditan, a specific 5-HT\n                      <jats:sub>1F<\/jats:sub>\n                      agonist, has gained approval as abortive therapy for migraine. This meta-analysis and trial sequential analysis (TSA) was performed to analyze efficacy and tolerability of lasmiditan therapy for episodic migraine.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>MATERIALS AND METHODS:<\/jats:title>\n                    <jats:p>Phase II and Phase III double-blinded placebo-controlled randomized controlled trials (RCTs) evaluating lasmiditan for episodic migraine were searched for from electronic databases. The risk of bias was estimated, data were extracted, and relative risk (RR) were calculated for efficacy and safety outcomes with a fixed\/random effect model. Forest plots and funnel plots were created. TSA graph was plotted. Therapeutic gain with lasmiditan was calculated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS:<\/jats:title>\n                    <jats:p>Six high-quality RCTs were included with 7122 patients. Compared to placebo, lasmiditan demonstrated a significant proportion of migraineurs reporting freedom from headache, most bothersome symptom, headache response, no disability, global impression \u201cvery much\/much better\u201d 2 h posttreatment and sustained pain freedom at 24 and 48 h with 50, 100, 200, and 400 mg doses (RR range = 1.26\u20132.50). 39.3% of patients in the lasmiditan group (RR = 2.43) reported one or more treatment-emergent adverse event (TEAE). Dizziness, somnolence, paresthesia, fatigue, nausea, vertigo, hypoesthesia, asthenia, muscular weakness, lethargy, and malaise had a high incidence (RR range = 3.16\u201312.77). Most TEAEs were mild to moderate. No vasoconstriction-related TEAE was reported.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSION:<\/jats:title>\n                    <jats:p>Lasmiditan demonstrated efficacy as abortive therapy for episodic migraine with central nervous system-related side effects.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/ijp.ijp_901_21","type":"journal-article","created":{"date-parts":[[2024,5,23]],"date-time":"2024-05-23T15:47:00Z","timestamp":1716479220000},"page":"397-406","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Lasmiditan abortive therapy for episodic migraine in Phase II\/III randomized clinical trials"],"prefix":"10.4103","volume":"54","author":[{"given":"Marya","family":"Ahsan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayaz Khurram","family":"Mallick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-2-20240903","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1186\/s10194-020-01208-0","article-title":"Lifting The Burden: The Global Campaign against Headache. Migraine remains second among the world's causes of disability, and first among young women: findings from GBD2019","volume":"21","author":"Steiner","year":"2020","journal-title":"J Headache Pain"},{"key":"R2-2-20240903","doi-asserted-by":"crossref","first-page":"6619","DOI":"10.1523\/JNEUROSCI.0373-15.2015","article-title":"Migraine: Multiple processes, complex pathophysiology","volume":"35","author":"Burstein","year":"2015","journal-title":"J Neurosci"},{"key":"R4-2-20240903","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1152\/physrev.00034.2015","article-title":"Pathophysiology of migraine: A disorder of sensory processing","volume":"97","author":"Goadsby","year":"2017","journal-title":"Physiol Rev"},{"key":"R5-2-20240903","first-page":"243","article-title":"Acute migraine headache: Treatment strategies","volume":"97","author":"Mayans","year":"2018","journal-title":"Am Fam Physician"},{"key":"R6-2-20240903","doi-asserted-by":"crossref","first-page":"4765","DOI":"10.1007\/s12325-020-01494-9","article-title":"Evaluation of patients with insufficient efficacy and\/or tolerability to triptans for the acute treatment of migraine: A systematic literature review","volume":"37","author":"Leroux","year":"2020","journal-title":"Adv Ther"},{"key":"R8-2-20240903","doi-asserted-by":"crossref","first-page":"515","DOI":"10.2147\/JPR.S132833","article-title":"Serotonin receptor agonists in the acute treatment of migraine: A review on their therapeutic potential","volume":"11","author":"Negro","year":"2018","journal-title":"J Pain Res"},{"key":"R9-2-20240903","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1007\/s40265-019-01225-7","article-title":"Lasmiditan: First approval","volume":"79","author":"Lamb","year":"2019","journal-title":"Drugs"},{"key":"R10-2-20240903","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1177\/0333102410370873","article-title":"Preclinical pharmacological profile of the selective 5-HT1F receptor agonist lasmiditan","volume":"30","author":"Nelson","year":"2010","journal-title":"Cephalalgia"},{"key":"R11-2-20240903","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s10194-020-01138-x","article-title":"Short-term efficacy and safety of lasmiditan, a novel 5-HT (1F) receptor agonist, for the acute treatment of migraine: A systematic review and meta-analysis","volume":"21","author":"Hou","year":"2020","journal-title":"J Headache Pain"},{"key":"R12-2-20240903","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1177\/0333102410375512","article-title":"Acute treatment of migraine with the selective 5-HT1F receptor agonist lasmiditan - A randomised proof-of-concept trial","volume":"30","author":"Ferrari","year":"2010","journal-title":"Cephalalgia"},{"key":"R13-2-20240903","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/S1474-4422(12)70047-9","article-title":"Efficacy and tolerability of lasmiditan, an oral 5-HT (1F) receptor agonist, for the acute treatment of migraine: A phase 2 randomised, placebo-controlled, parallel-group, dose-ranging study","volume":"11","author":"F\u00e4rkkil\u00e4","year":"2012","journal-title":"Lancet Neurol"},{"key":"R14-2-20240903","doi-asserted-by":"crossref","first-page":"e2222","DOI":"10.1212\/WNL.0000000000006641","article-title":"Lasmiditan is an effective acute treatment for migraine: A phase 3 randomized study","volume":"91","author":"Kuca","year":"2018","journal-title":"Neurology"},{"key":"R15-2-20240903","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1093\/brain\/awz134","article-title":"Phase 3 randomized, placebo-controlled, double-blind study of lasmiditan for acute treatment of migraine","volume":"142","author":"Goadsby","year":"2019","journal-title":"Brain"},{"key":"R16-2-20240903","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1177\/0333102421989232","article-title":"Randomized, controlled trial of lasmiditan over four migraine attacks: Findings from the CENTURION study","volume":"41","author":"Ashina","year":"2021","journal-title":"Cephalalgia"},{"key":"R17-2-20240903","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1111\/head.14122","article-title":"Phase 2 randomized placebo-controlled study of lasmiditan for the acute treatment of migraine in Japanese patients","volume":"61","author":"Sakai","year":"2021","journal-title":"Headache"},{"key":"R20-2-20240903","first-page":"700","article-title":"Interpreting estimates of treatment effects: Implications for managed care","volume":"33","author":"Faraone","year":"2008","journal-title":"P T"},{"key":"R27-2-20240903","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s13311-018-0615-6","article-title":"Targeted 5-HT (1F) therapies for migraine","volume":"15","author":"Vila-Pueyo","year":"2018","journal-title":"Neurotherapeutics"},{"key":"R28-2-20240903","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1177\/0333102419864132","article-title":"Interim results of a prospective, randomized, open-label, Phase 3 study of the long-term safety and efficacy of lasmiditan for acute treatment of migraine (the GLADIATOR study)","volume":"39","author":"Brandes","year":"2019","journal-title":"Cephalalgia"},{"key":"R29-2-20240903","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s10194-012-0428-7","article-title":"The 5-HT1F receptor agonist lasmiditan as a potential treatment of migraine attacks: A review of two placebo-controlled phase II trials","volume":"13","author":"Tfelt-Hansen","year":"2012","journal-title":"J Headache Pain"}],"container-title":["Indian Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/ijp.ijp_901_21","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T18:40:38Z","timestamp":1787769638000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/ijp.ijp_901_21"}},"subtitle":["A meta-analysis"],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":19,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.4103\/ijp.ijp_901_21","relation":{},"ISSN":["0253-7613"],"issn-type":[{"value":"0253-7613","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]}}}